SRRK stock forecast, quote, news & analysis

Key Takeaways

• Scholar Rock shares have fallen roughly 11% over the past 30 days, with the latest price near $41.39 after trading around $46.65 about a month earlier.
• The decline follows the September 11, 2026 FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for spinal muscular atrophy, in a classic "sell the news" pattern after a strong pre-approval rally.
• Over the past three months, the stock has dropped roughly 22% from its late-August 52-week high of $61.76 (intraday).
• Wall Street remains largely constructive, with analyst price targets ranging from $60 to $77, but near-term trading has been driven by profit-taking and broader small-cap biotech volatility.
• Upcoming catalysts include early ISEMBYLD launch metrics, a European Union regulatory review, and SRK-439 Phase 1 data expected in late 2026.

Scholar Rock (SRRK) Company Overview and Market Position

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on rare, severe neuromuscular diseases. The company is a recognized leader in myostatin biology, developing monoclonal antibodies that selectively target the latent forms of protein growth factors to help regulate muscle mass and strength.

Its lead product, ISEMBYLD (apitegromab-mstn), is a fully human monoclonal antibody that inhibits myostatin activation. In September 2026, it became the first and only muscle-targeted therapy approved by the U.S. Food and Drug Administration for adults and children ages two and older with spinal muscular atrophy (SMA) who are receiving an SMN2-targeted treatment. Beyond SMA, Scholar Rock is advancing apitegromab in facioscapulohumeral muscular dystrophy (FSHD) and developing SRK-439, a subcutaneously administered myostatin inhibitor. Investors follow the stock closely because it sits at the center of a high-value rare-disease franchise transitioning from clinical development to commercialization.

Scholar Rock (SRRK) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, SRRK has declined approximately 11%, falling from a closing level near $46.65 to roughly $41.39. The move lower has been gradual rather than a single-day shock, with the stock grinding down through late September and October.

The longer trend is more pronounced. Over the last quarter, the shares have fallen roughly 22%, retreating from the 52-week intraday high of $61.76 reached on August 26, 2026. That peak came before the FDA approval was formally announced, underscoring how much of the positive regulatory outcome had already been priced into the stock. Since then, SRRK has entered a corrective phase, retracing a meaningful portion of its multi-year advance as the market digests the company's shift into its commercial launch phase.

What Drove SRRK Stock Price in the Last 30 Days

The single most important event was the September 11, 2026 FDA approval of ISEMBYLD for SMA. Because the approval had been widely anticipated following a March 2026 BLA resubmission, much of the rally occurred in the weeks leading up to the decision. Once the milestone was confirmed, traders took profits, and the stock drifted lower in a textbook "buy the rumor, sell the news" move.

Post-approval, attention shifted to launch execution, pricing, and reimbursement, areas where a newly commercial-stage biotech faces execution risk. Investor focus on initial commercial uptake, payer negotiations, and patient access contributed to cautious positioning. Broader weakness in the small-cap biotechnology sector also weighed on sentiment.

Analyst commentary remained supportive during this period. Raymond James reiterated a Strong Buy rating with a $72 price target in early October following the company's resubmission of its European marketing application, while other firms maintained price targets between $60 and $77. Despite this, the shares continued to soften, indicating that short-term price action was dominated by technical and sentiment-driven selling rather than a deterioration in the underlying regulatory story.

What Drove SRRK Stock Performance Over the Last Quarter

The quarterly decline reflects a valuation reset after an extended rally. Scholar Rock shares appreciated sharply over several years as apitegromab progressed through Phase 3 and regulatory review, and the stock peaked near $61.76 in late August 2026 as the FDA action date approached. With approval now secured, the market has been re-evaluating the stock from a clinical-catalyst framework to a commercial-execution framework, a transition that frequently produces volatility.

Additional developments shaped the quarter. In August 2026, the company removed the Catalent Indiana fill-finish facility from its BLA under FDA guidance and relied on a second, U.S.-based fill-finish site. Scholar Rock also reported second-quarter results showing no revenue, a net loss of $109.9 million, and cash and marketable securities of $492.1 million, while continuing to fund its pipeline. These factors, combined with sector-wide rotation out of high-multiple biotech names, contributed to the multi-month pullback.

Trending AI Robots

For traders seeking a more systematic approach to volatile names like SRRK, Tickeron's Trending AI Robots page offers a curated look at AI-driven trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this dedicated section. These bots differ in strategy, timeframe, and performance metrics, allowing users to explore approaches that range from short-term swing trading to longer-term trend following. Because the selection emphasizes bots that are currently demonstrating strong results, the page provides a focused starting point for investors interested in data-driven market analysis. Browsing the section can help identify strategies aligned with a specific risk tolerance and time horizon.

SRRK Stock Forecast Drivers: What Investors Should Watch Next

The primary focus in the months ahead is ISEMBYLD's commercial launch, including early prescription trends, patient access, and payer coverage. Investors will also track the European regulatory process after the resubmission of the marketing authorization application, with a CHMP opinion expected in the first half of 2027.

Pipeline catalysts matter as well. Topline data from the Phase 1 study of SRK-439 in healthy volunteers are anticipated in late 2026, and progress in the Phase 2 FORGE trial in FSHD could broaden the apitegromab franchise. Quarterly financial updates will offer visibility into launch spending, cash runway, and early revenue recognition as the company transitions toward commercial operations. Macroeconomic conditions, biotech risk appetite, and competitive dynamics in the SMA treatment landscape will also influence sentiment. These factors should be monitored carefully, as clinical-stage and newly commercial biotech companies can experience sharp price swings tied to binary events.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations